Sign in
AMGN-AMGEN INC

Amgen Reports Strong Q4 and Full-Year Earnings Amid FDA Setbacks, Eyes Growth in Obesity Pipeline and Rare Diseases

Friday

14 February, 2025

Amgen's fourth-quarter earnings reveal a resilient performance with $9.1 billion in revenue, despite facing FDA setbacks and halted trials. As the company eyes growth in its obesity pipeline and rare diseases, can it navigate these challenges while maintaining investor confidence?

article image for AMGN

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
59
Key Takeaways
  • Amgen reported fourth-quarter earnings surpassing expectations, with revenues reaching $9.1 billion driven by strong product sales.
  • The company experienced a 19% increase in full-year revenue, indicating solid financial stability.
  • Despite challenges with clinical trials, Amgen is optimistic about its pipeline, particularly the bispecific molecule MariTide.
  • Projections for 2025 suggest earnings between $20 and $21.20 per share, alongside significant revenue growth.
  • Concerns about competition and recent setbacks may create volatility for investors considering Amgen's stock.
More on AMGEN INC
Read more insights on AMGEN INC

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.